Skip to main content
OpenTrials
Completed

NCT Number: NCT00168155

Study of 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Tom Baker Cancer Centre

Calgary, Alberta, T2N 4N2, Canada

About this study

When colon or rectal cancer has spread to the liver, the cancer in the liver can sometimes be removed surgically. However, the cancer has a chance or reoccurring in the liver or elsewhere in the body. This study will determine if giving chemotherapy treatment before the surgery can reduce the chances that the cancer will come back.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • stage IV colorectal cancer isolated to the liver
  • one measurable lesion
  • metastases are completely resectable or amenable to ablation
  • Karnofsky >70
  • Adequate bone marrow function
  • adequate hepatic function
  • adequate renal function
  • informed consent

Exclusion criteria

  • primary tumor not controlled by locoregional treatments
  • bilateral portal vein and/or hepatic artery involvement
  • previous chemotherapy directed at treatment of metastatic colorectal cancer
  • underlying acute or chronic liver disease
  • Gilbert's disease
  • patients receiving phenytoin or phenobarbital prophylaxis
  • presence of any concurrent medical or psychiatric condition that serves as a contraindication to surgery or chemotherapy
  • pregnancy
  • malignancy other than basal cell or squamous cell carcinoma of the skin within the preceding 5 years
  • use of another investigational medication concurrently or within 4 months of enrollment

Treatment and study plan

perioperative chemotherapy

Drug

Primary outcomes

  1. disease free survival

Sponsors and collaborators

Lead sponsor

Alberta Health services

Other

Collaborators

  • Pfizer

Registry information

Official study title

Phase 2 Study of Neoadjuvant 5-FU + Leucovorin + CPT-11 in Patients With Resectable Liver Metastases From Colorectal Adenocarcinoma

Important dates

Study start
2002
Primary completion
2009
Study completion
2009
First posted
Sep 15, 2005
Registry last updated
Jan 19, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.